HAYA Therapeutics is a precision therapeutics company that discovers and develops innovative tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. The company’s discovery engine focuses on long non-coding RNAs (lncRNAs) within the “dark matter” of the human genome -- key tissue and cell-specific drivers of fibrosis and other disease processes -- to identify novel targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA’s lead therapeutic candidate is an antisense molecule targeting Wisper, a cardiac-enriched master driver of fibrosis, which has shown in preclinical testing the ability to halt and potentially reverse the fibrotic processes underlying heart failure.
HAYA is headquartered at the life sciences park Biopôle SA in Lausanne, Switzerland and recently expanded its footprint to the U.S., becoming a resident at Johnson & Johnson Innovation JLABS in San Diego. HAYA is led by a world-class team of experts in lncRNA biology and fibrotic disease, and is supported by a strong investor consortium.
The company is also developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in other tissues, including lungs, kidney, liver, and the micro-environment of solid tumor cancers. Headquartered at the life sciences park Biopôle SA in Lausanne, Switzerland, HAYA is led by a world-class team of experts in lncRNA biology and fibrotic disease, and is supported by a strong investor consortium.